The Journal of Practical Medicine >
Effects of indobuprofen combined with nicodil on inflammatory factors， myocardial injury markers and platelet function in patients with ACS after PCI
Received date: 2024-02-04
Online published: 2024-06-14
Objective To investigate the efficacy of indobuprofen combined with nicodil for the treatment of acute coronary syndromes （ACS） and the effects of percutaneous coronary intervention on patients Effects of myocardial injury markers， platelet function and inflammatory factors after intervention （PCI）. Method A total of 150 patients with ACS admitted to the hospital from January 2021 to December 2022 were divided into groups according to different treatment methods. The control group （n = 75） was given nicodil combined with antiplatelet therapy， and the study group （n = 75） was given indobufen combined with nicodil combined with antiplatelet therapy. Both groups were treated for 2 weeks. The clinical efficacy of the two groups was compared， the changes of myocardial injury markers， platelet function and inflammatory factors before and after treatment were monitored， and the total incidence of adverse reactions was recorded. Results The total effective rate of the group treated with nicodil combined with indobufen was 98.67% higher than that of the control group treated with nicodil alone， 90.67% （χ2 = 4.754， P < 0.05）. The levels of myocardial injury markers such as cTnI and CK-MB in the study group after treatment were lower than those in the control group （t = 15.492， 3.250， P < 0.05）. The levels of platelet function indexes such as CD62p， CD63， GPⅡb/Ⅲa in the study group after treatment were lower than those in the control group （t = 2.034， 3.257， 2.221， P < 0.05）. The levels of CRP， TNF-α， IL-6 and other inflammatory factors in the study group were lower than those in the control group after treatment （t = 21.862， 3.378， 2.131， P < 0.05）. The total incidence of adverse reactions after treatment was 4.00% in the study group and 2.67% in the control group （P > 0.05）. Conclusion The efficacy of indobufien combined with nicodil in the treatment of ACS is better than that of nicodil alone， and it can improve myocardial injury and platelet function after PCI， inhibit the release of inflammatory factors， and the incidence of adverse reactions is lower.
Shuhong RUI , Chenfang WANG , Yunhe LI , Junlan PAN , Jianlou WANG . Effects of indobuprofen combined with nicodil on inflammatory factors， myocardial injury markers and platelet function in patients with ACS after PCI[J]. The Journal of Practical Medicine, 2024 , 40(12) : 1706 -1711 . DOI: 10.3969/j.issn.1006-5725.2024.12.016
| 1 | 王紫斓，涂应锋，于波. 支架置入术后再发急性冠状动脉综合征的研究进展［J］. 中国介入心脏病学杂志， 2021，29（8）：462-467. doi:10.3969/j.issn.1004-8812.2021.08.007 |
| 2 | AKTüRK I? F， YILDIZ C， KARABULUT D，et al. Is the revascularisation strategy and outcome different in patients with acute coronary syndrome in COVID-19 pandemic era： a tertiary centre experience［J］. Acta Cardiol， 2021，77（8）：720-728. doi:10.1080/00015385.2021.1967614 |
| 3 | 董扬，张芬，王文标，等. 老年急性心肌梗死患者PCI和非PCI治疗预后比较［J］. 中华全科医学， 2022，159（4）：721-723. |
| 4 | FALLAHZADEH A， SHEIKHY A， AEIN A，et al. Outcome of Percutaneous Coronary Intervention in Old Patients Presenting with Acute Coronary Syndrome［J］. Arch Iran Med， 2022，25（8）：523-532. doi:10.34172/aim.2022.84 |
| 5 | 边亚，刘广阔，李志涛，等. 尼可地尔对老年T2DM合并CHD患者心肌保护作用［J］. 中国急救复苏与灾害医学杂志， 2023，18（5）：583-586. doi:10.3969/j.issn.1673-6966.2023.05.005 |
| 6 | 饶琰，雷阳. 尼可地尔联合双联抗血小板药物对急性NSTEMI患者PCI术后的影响［J］. 深圳中西医结合杂志， 2021，31（13）：162-164. |
| 7 | VINGE E， BJ?RKMAN S. Compared effects of the two antiinflammatory drugs indoprofen and lonazolac on thromboxane generation and on platelet aggregation， related to plasma concentrations after single oral doses［J］. Acta Pharmacol Toxicol，1986，59（3）：165-174. doi:10.1111/j.1600-0773.1986.tb00150.x |
| 8 | 中华中医药学会内科分会心病专业委员会. 中医心病之心绞痛诊断与疗效标准［J］. 中国医药学报， 2004，19（10）：581-583. doi:10.3969/j.issn.1673-1727.2004.10.001 |
| 9 | 中医临床诊疗指南制修订项目不稳定型心绞痛项目组. 不稳定型心绞痛中医诊疗专家共识［J］. 中医杂志， 2022，7（63）：695-700. |
| 10 | YAMAMOTO K， NATSUAKI M， MORIMOTO T， et al. Coronary Artery Disease Without Standard Cardiovascular Risk Factors［J］. Am J Cardiol， 2022，164：34-43. doi:10.1016/j.amjcard.2021.10.032 |
| 11 | 刘江萍，木胡牙提. 急性冠脉综合征流行病学及危险因素的研究进展［J］. 国际心血管病杂志， 2019，46（1）：1-3，7. doi:10.3969/j.issn.1673-6583.2019.01.001 |
| 12 | 张嵚垚，马淑梅. 静脉注射尼可地尔对行经皮冠状动脉介入治疗的不稳定性心绞痛患者的心肌保护作用［J］. 实用药物与临床， 2020，23（1）：77-81. |
| 13 | 张紫萍，方广，郭秀彩. 从《冠心病合理用药指南》看尼可地尔在冠心病治疗中的作用［J］. 实用医学杂志， 2020，36（22）：3033-3037. doi:10.3969/j.issn.1006-5725.2020.22.001 |
| 14 | 崔高伟，金会群，张利卫，等. 尼可地尔联合双联抗血小板药物治疗急性非ST段抬高型心肌梗死PCI术后患者的效果［J］. 河南医学研究， 2021，30（34）：6477-6479. doi:10.3969/j.issn.1004-437X.2021.34.047 |
| 15 | 徐辉. 吲哚布芬在经皮冠状动脉支架植入术后急性冠脉综合征患者中的疗效与安全性研究［D］. 青岛：青岛大学，2024. |
| 16 | SHEN L， QIU L， LIU J，et al. Clinical Implications of Nicorandil Combined with Trimetazidine in Patients with Coronary Heart Disease： A Real-World Observational Study［J］. Adv Ther， 2021，39（1）：655-673. doi:10.1007/s12325-021-01987-1 |
| 17 | CHOE J C， OH J H， LEE H C，et al. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention： a randomised trial［J］. Acta Cardiol， 2023，78（8）：880-888. doi:10.1080/00015385.2022.2129592 |
| 18 | PAN Y， MENG X， CHEN W， et al.Indobufen versus aspirin in acute ischaemic stroke （INSURE）： rationale and design of a multicentre randomised trial［J］. Stroke Vasc Neurol， 2022， 7（5）：457-461. doi:10.1136/svn-2021-001480 |
| 19 | QUESADA O， ELBOUDWAREJ O， NELSON M D，et al. Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease［J］. Am Heart J Plus， 2022，13：100115. doi:10.1016/j.ahjo.2022.100115 |
| 20 | WU H， XU L， ZHAO X，et al. OPTION Investigators. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation （OPTION）： A Randomized， Open-Label， End Point-Blinded， Noninferiority Trial［J］. Circulation， 2023，147（3）：212-222. doi:10.1161/circulationaha.122.062762 |
| 21 | LEE C C， CHANG S N， TEHRANI B，et al. Use of nicorandil is associated with increased risk of incident atrial fibrillation［J］. Aging （Albany NY）， 2022，14（17）：6975-6992. doi:10.18632/aging.204259 |
| 22 | 代世摩，戚志勇，齐保振，等. 沙库巴曲缬沙坦对血小板活化，动脉血栓形成的作用［J］. 中国分子心脏病学杂志， 2023，23（3）：5380-5386. |
| 23 | SHI Q P， LUO X Y， ZHANG B，et al. Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention： An open-label crossover study［J］. Front Pharmacol，2022，13：950-979. doi:10.3389/fphar.2022.950719 |
| 24 | HUANG D， WU H， ZHOU J， et al. Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction： Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil （CLEAN） trial［J］. Am Heart J，2021，244：86-93. doi:10.1016/j.ahj.2021.11.005 |
| 25 | PAN Y， MENG X， CHEN W，et al. Indobufen versus aspirin in acute ischaemic stroke （INSURE）： rationale and design of a multicentre randomised trial［J］. Stroke Vasc Neurol，2022，7（5）：457-461. doi:10.1136/svn-2021-001480 |
| 26 | 张慧垒，邢疆波，李长路. 益气舒心丸联合他汀类药物对ACS病人PCI术后HSP60，hs-CRP，TNF-α指标的影响［J］. 中西医结合心脑血管病杂志， 2020，18（19）：3234-3235. |
| 27 | LI K， YANG H， JIANG Z，et al. Effect of proximal femoral nail antirotation on clinical outcome， inflammatory factors and myocardial injury markers in patients with femoral trochanteric fracture［J］. Am J Transl Res， 2022，14（7）：4795-4803. |
| 28 | SHI L， CHEN L， QI G，et al. Effects of Intracoronary Nicorandil on Myocardial Microcirculation and Clinical Outcomes in Patients with Acute Myocardial Infarction： A Meta-Analysis of Randomized Controlled Trials［J］. Am J Cardiovasc Drugs，2020，20（2）：191-198. doi:10.1007/s40256-019-00368-y |
/
| 〈 |
|
〉 |